Clinical trials for oncology drugs are running into unique challenges as protocols become more complex and as the number of new investigational agents continues to outpace all other drugs, according to a recent study by Tufts University researchers.
The study, “Protocol complexity and patient enrollment intensity challenges in oncology trials,” was conducted by Zachary Smith, a senior research analyst at Tufts, and led by Kenneth Getz, professor and director of the Tufts Center for the Study of Drug Development.
